What factors do you consider when choosing between vimseltinib and pexidartinib for tenosynovial giant cell tumor (TGCT) patients?

Pexidartinib has much longer Phase 4 follow-up data than vimseltinib. Both drugs have comparable efficacy. The tolerance, especially LFT abnormalities, is not an issue with the new lower dose pexidartinib. The distinguishing factor remains the REMS program. So it is a matter of personal practice/pre...